Belgium Pharmaceuticals and Healthcare Report Q3 2015

Belgium Pharmaceuticals and Healthcare Report Q3 2015

Includes 3 FREE quarterly updates

BMI View:
With structurally higher prices than many regional markets and quickly rising pharmaceutical onsumption, Belgium will continue to present a high level of potential reward to drugmaker. Notably, a distinct lack of price transparency within the pharmaceutical value chain will combine with patient and prescriber bias towards patented drugs to hamper initiatives that seek to reduce public sector pharmaceutical reimbursement spending. However, an increasingly credible threat of domestic terrorism and the destabilising potential of Flemish separatism will weigh on the country's risk profile, increasing the
costs and administrative burden borne by investors.


Headline Expenditure Projections
- Pharmaceuticals: From EUR5.78bn (USD7.75bn) in 2014 to EUR5.80bn (USD6.38bn) in 2015; 0.24% in local currency terms and -17.7% in US dollar terms. Forecast revised upwards from previous quarter.
- Healthcare: From EUR43.87bn (USD58.77bn) in 2014 to EUR44.96bn (USD49.46bn) 2015; +2.5% in local currency terms and -15.8% in US dollar terms. Forecast revised upwards from previous quarter.
BMI Industry View 7
SWOT 9
Political . 11
Economic .. 12
Industry Forecast .. 13
Pharmaceutical Market Forecast . 13
Table: Pharmaceutical Sales, Historical Data And Forecasts (Belgium 2011-2019) 15
Healthcare Market Forecast . 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Belgium 2011-2019) . 17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Belgium 2011-2019) . . 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Belgium 2011-2019) . . 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Belgium 2011-2019) . 20
Patented Drug Market Forecast .. 20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Belgium 2011-2019) . . 22
Generic Drug Market Forecast 22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Belgium 2011-2019) 24
OTC Medicine Market Forecast .. 25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Belgium 2011-2019) . 27
Pharmaceutical Trade Forecast .. 27
Table: Pharmaceutical Trade Data And Forecasts (Belgium 2013-2019) . . 29
Table: Pharmaceutical Trade Data And Forecasts local currency (Belgium 2013-2019) . 29
Key Risks To BMI's Forecast Scenario 30
Macroeconomic Forecasts .. 31
Economic Analysis .. 31
Table: GDP By Expenditure (Belgium 2012-2019) . 35
Industry Risk Reward Indices 36
Western Europe Risk/Reward Index 36
Belgium Risk/Reward Index .. 40
Rewards .. 40
Risks . 41
Market Overview 42
Industry Trends And Developments .. 43
Healthcare Sector . 43
Table: Healthcare Resources (Belgium 2009-2014) . 44
Table: Healthcare Personnel (Belgium 2009-2014) . 45
Table: Healthcare Activity (Belgium 2009-2014) 45
Epidemiology . 46
Public Health Developments .. 47
Health Insurance .. 48
Healthcare Financing .. 49
Research and Development . 50
Clinical Trials 52
Regulatory Development .. 54
Regulatory Developments 57
Intellectual Property Issues . 58
Pricing Regime .. 58
Reimbursement Regime 60
Table: Reimbursements by Category, 2009 . 62
Table: Price Build-Up for OTC Medicines . 64
Competitive Landscape . 65
Pharmaceutical Sector . 65
Pharmaceutical Distribution .. 66
Pharmaceutical Retail Sector . 66
Company Profile . 68
GlaxoSmithKline (GSK) . 68
Pfizer . 71
Sanofi . 74
Novartis . 76
Merck & Co .. 78
UCB Pharma 80
Galapagos . 84
Janssen Pharmaceutica . 87
Omega Pharma 90
Solvay (Abbott) 94
Demographic Forecast .. 97
Table: Population Headline Indicators (Belgium 1990-2025) . . 98
Table: Key Population Ratios (Belgium 1990-2025) 98
Table: Urban/Rural Population & Life Expectancy (Belgium 1990-2025) . 99
Table: Population By Age Group (Belgium 1990-2025) . . 99
Table: Population By Age Group % (Belgium 1990-2025) . 100
Glossary 102
Methodology .. 104
Pharmaceutical Expenditure Forecast Model .. 104
Healthcare Expenditure Forecast Model 104
Notes On Methodology .. 105
Risk/Reward Index Methodology . 106
Index Overview 107
Table: Pharmaceutical Risk/Reward Index Indicators 107
Indicator Weightings . 108
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.